At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
FLOT Chemotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dragon III- Phase 2: The Preliminary Efficacy Study of FLOT Versus SOX Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer: Open-label, Randomized Controlled Trial
In Brief
A Phase 2 clinical trial evaluating FLOT Chemotherapy and SOX Chemotherapy for Gastric Cancer and Chemotherapy Effect. Completed, enrolled 74 participants across 1 site.
Detailed Summary
Safety and efficacy study of neoadjuvant chemotherapy (FLOT versus SOX) for gastric cancer patients in high volume center of China
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Chemotherapy Effect
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartAug 2018
Primary CompletionMar 2020
Study CompletionMay 2025
TodayJul 2026
First PostedAug 17, 2018
Enrollment StartAug 24, 2018
Primary CompletionMar 31, 2020
Study CompletionMay 8, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.9 years ago
Interventions
FLOT Chemotherapydrug
5-FU+Leucovorin+Docetaxel+Oxaliplatin
SOX Chemotherapydrug
Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)